Tandem Diabetes Stock Price, News & Analysis

Tandem Diabetes Care (NASDAQ:TNDM) announced that users of its t:slim X2 insulin pump have delivered over 1 million insulin boluses via the t:connect app within a month of its launch. This app, the first FDA-cleared one for initiating insulin delivery on smartphones, supports both iOS and Android on approximately 30 devices. Users can activate this feature at no additional cost. CEO John Sheridan emphasized the importance of innovative technology for improving diabetes management.

Tandem Diabetes Care (NASDAQ: TNDM) reported strong Q2 2022 results, with worldwide sales up 16% to $200.3 million and a 40% increase in its installed base, totaling over 375,000 customers. U.S. sales rose 14% to $145.7 million, and gross profit increased 10% to $101.9 million. However, the company updated its 2022 sales guidance down to $835 million - $845 million, lower than previous estimates. Furthermore, a net loss of $15.1 million was reported compared to a $4.0 million income in the same quarter last year. Adjusted EBITDA also saw a decline.

Tandem Diabetes Care (NASDAQ:TNDM) has acquired Capillary Biomedical, an infusion set developer, aiming to enhance its insulin delivery portfolio. The acquisition focuses on expanding options for insulin pump wearability, with a commitment to developing innovative solutions that extend wear time and reduce user burden. Although the technology is still in development and not yet available commercially, the company sees potential synergies in integrating Capillary's solutions into its product offerings. Financial terms of the transaction remain undisclosed.

Tandem Diabetes Care, Inc. (NASDAQ: TNDM) is set to release its second quarter 2022 results on August 3, 2022, after market close. A conference call will follow at 4:30 PM ET to discuss financial and operating results. The event will be accessible via webcast on the company's Investor Center website, with an archive available for 30 days post-event. Tandem is dedicated to enhancing the lives of those living with diabetes through innovative insulin delivery solutions, such as the t:slim X2 insulin pump.

Tandem Diabetes Care, Inc. (NASDAQ: TNDM) announced the appointment of Myoung Cha and Joao Malagueira as independent directors, effective June 15, 2022. John Sheridan, CEO, highlighted their extensive experience as valuable assets for the company's global expansion and product development. Cha brings over 17 years in healthcare, previously at Apple and McKinsey & Company. Malagueira has 25 years in diabetes and medical devices, currently at Hologic, with a strong record in EMEA markets. Their leadership is expected to strengthen Tandem's strategic direction.

Tandem Diabetes Care (NASDAQ:TNDM) presented positive real-world data from the Control-IQ Observational study at the American Diabetes Association's 82nd Scientific Sessions in New Orleans. The data revealed significant improvements in diabetes management among a diverse cohort using the t:slim X2 insulin pump with Control-IQ technology. Highlights include enhanced quality of life, significant glycemic improvements across various ethnic groups, and demonstrated benefits regardless of prior therapy. The findings emphasize Tandem's commitment to advancing diabetes technology for all patients.

Tandem Diabetes Care, Inc. (NASDAQ: TNDM) will present a company update at the Piper Sandler Virtual Diabetes Symposium on Wednesday, May 25, 2022, at 11:00 AM ET. The presentation will be webcast live and archived for 30 days on their Investor Center website.

Tandem, based in San Diego, California, specializes in insulin delivery and diabetes technology, offering innovative products like the t:slim X2 insulin pump with Control-IQ technology.

Tandem Diabetes Care, Inc. (TNDM) reported Q1 2022 financial results, with sales rising by 25% to $175.9 million. Worldwide pump shipments increased by 11% to 28,095 units. Cash and equivalents reached $635.4 million, up $11.6 million this quarter. The company updated its 2022 guidance, estimating sales between $850 million and $865 million, reflecting a growth of 21% to 23%. Gross margins are projected at 54%. However, the operating loss increased to $15.3 million, and net loss reached $14.7 million, indicating challenges amidst growth.

Tandem Diabetes Care (NASDAQ:TNDM) announced positive real-world data for its t:slim X2 insulin pump with Control-IQ technology at the 15th International Conference on Advanced Technologies and Treatments for Diabetes in Barcelona. Results from the Control-IQ Observational study showed improvements in glycemic control and quality of life for 1,913 participants. Additionally, 95% of users transitioning from multiple daily injections successfully initiated Control-IQ technology within 14 days. The data emphasizes the technology's effectiveness across various age groups and prior delivery methods.